886364-53-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-BROMOPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHANONE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
1-(4-BROMOPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHANONE is used as a building block in the synthesis of heterocyclic compounds, which are important in various chemical and pharmaceutical applications due to their diverse chemical properties and biological activities.
Used in Medicinal Chemistry and Drug Discovery:
1-(4-BROMOPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHANONE is used as a structural component in the design and development of new drug candidates, leveraging its unique features to enhance the pharmacological properties of potential therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 886364-53-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 4 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 886364-53:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*4)+(2*5)+(1*3)=220
220 % 10 = 0
So 886364-53-0 is a valid CAS Registry Number.
886364-53-0Relevant academic research and scientific papers
TGF-betaR1 inhibitor and application thereof
-
Paragraph 1041; 1043-1045, (2020/06/09)
The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.
